Recipient immune system and malignant hematologic cells

The term Recipient immune system and malignant hematologic cells refers to the complex physiological and pathological environment found in patients with blood cancers, particularly in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). This is not a single molecular target but a systemic biological context involving the interplay between the host's immune cells, introduced donor immune cells, and the cancerous hematologic population (Appelbaum, 2001, Nature). The primary therapeutic goal in this setting is to harness the Graft-versus-Leukemia (GvL) effect, where immune cells identify and eliminate residual malignant cells, while simultaneously preventing Graft-versus-Host Disease (GvHD), where the immune response attacks the recipient's healthy tissues (Ferrara et al., 2009, Lancet). Because this represents a broad cellular system rather than a specific protein, it is considered an incorrect designation for a canonical drug target. Instead, pharmacological agents like calcineurin inhibitors or monoclonal antibodies are used to target specific molecules within this system to balance efficacy and toxicity (Zeiser & Blazar, 2017, NEJM).

Other names

Host immune environmentHematologic malignancy microenvironmentGraft-versus-host/leukemia axisRecipient hematopoietic system

Therapeutic interventions in this context aim to modulate the interaction between immune effector cells and target cells to induce a graft-versus-leukemia (GvL) effect while suppressing graft-versus-host disease (GvHD) through systemic immunosuppression or targeted depletion of specific cell subsets.